MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation announced today its intent to develop the Promega OncoMate™ microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, ...
First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients Itasca (IL), United States, 15 September 2025 – Biocartis ...
MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation today announced FALCO biosystems of Kyoto, Japan, a core business company of FALCO HOLDINGS, working in collaboration with Promega microsatellite ...
CDx IVD kit will be used to identify patients with the MSI biomarker who may be eligible for potential treatment with Jemperli (dostarlimab-gxly) MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation ...
Promega Corporation today announced it has entered into a global collaboration with Merck, known as MSD outside the United States and Canada, to develop Promega’s microsatellite instability (MSI) ...
CDx IVD kit will be used to identify patients with the MSI biomarker who may be eligible for potential treatment with Jemperli (dostarlimab-gxly) Promega Corporation today announced it plans to ...
Promega Corporation announced today its intent to develop the Promega OncoMate microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, Incyte's anti-PD-1 drug candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback